We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions.
- Authors
Duminuco, Andrea; Nardo, Antonella; Orofino, Alessandra; Giunta, Giuliana; Conticello, Concetta; Del Fabro, Vittorio; Chiarenza, Annalisa; Parisi, Marina S.; Figuera, Amalia; Leotta, Salvatore; Milone, Giuseppe; Cupri, Alessandra; Cambria, Daniela; Di Raimondo, Francesco; Romano, Alessandra; Palumbo, Giuseppe A.
- Abstract
Background: Managing SARS‐CoV‐2 infection in frail and immunosuppressed patients still represents an open challenge, but, starting from the phase 3 PROVENT study, prophylaxis with tixagevimab‐cilgavimab has improved the approach in this category of patients, guaranteeing a better outcome and inferior mortality. Real‐life data in a heterogeneous cohort are few. Methods: The aim of this study is to evaluate the benefit of prophylaxis with tixagevimab‐cilgavimab in a cohort of 202 patients affected by different hematological diseases (lymphoproliferative, myeloproliferative, autoimmune, patients recently receiving a bone marrow transplant), active (with ongoing treatment), or in watch‐and‐wait strategy, followed in our center, during a median follow‐up of 249 (45‐325) days. Results: An incidence of 44 breakthrough infections (21.8%) is reported, with no treatment‐related adverse effects. Age ≥70 years, ongoing treatment (above all with monoclonal antibodies), baseline lymphoproliferative disorders, and prior virus exposure are identified as risk factors related to subsequent infection (p < 0.05). Moreover, the incidence is higher in low/nonresponse to prior vaccination (p =.002). Patients treated with tixagevimab‐cilgavimab had a mild course of the infection and a reduction of the duration compared with preprophylaxis infection (11 vs. 15 days, p <.001). The concurrent treatment with anti‐CD20 monoclonal antibodies and B–non‐Hodgkin lymphoma still confers a higher duration of infection despite prophylaxis. No deaths attributable to the infection occurred. Conclusion: Prophylaxis treatment seems to be a valid and safe strategy, although not preventing breakthrough infection, but the severe complications associated with the infection and the possible delays in administering lifesaving therapies from long positivity. The use of tixagevimab‐cilgavimab improved the management of immunocompromised patients with a high risk of severe SARS‐CoV‐2 disease. In a real‐world setting, it confirmed its role not only in preventing the occurrence of breakthrough infection, but also, above all, avoiding the severe complications associated and reducing the total days of positivity.
- Subjects
BREAKTHROUGH infections; BLOOD diseases; SARS-CoV-2; MONOCLONAL antibodies; BONE marrow
- Publication
Cancer (0008543X), 2024, Vol 130, Issue 1, p41
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.35005